Clemens J D, Sack D A, Harris J R, Chakraborty J, Khan M R, Stanton B F, Kay B A, Khan M U, Yunus M, Atkinson W
Lancet. 1986 Jul 19;2(8499):124-7. doi: 10.1016/s0140-6736(86)91944-6.
The protective efficacy of oral B subunit killed whole-cell (BS-WC) and killed whole-cell (WC) cholera vaccines was assessed in 63 498 Bangladeshi children aged 2-15 years and women aged over 15 years. Each received three doses of BS-WC, WC, or placebo in a randomised, double-blinded fashion. Surveillance for cases seeking medical care up to six months after the third dose revealed 26 cases of confirmed cholera in the placebo group, 4 cases in the BS-WC group (protective efficacy 85%; p less than 0.0001), and 11 cases in the WC group (protective efficacy 58%; p less than 0.01). For each vaccine protective efficacy was consistent in different age-groups (2-10 years versus greater than 10 years) and for different severities of cholera.
在63498名2至15岁的孟加拉国儿童以及15岁以上的女性中评估了口服B亚单位全细胞（BS-WC）霍乱疫苗和全细胞（WC）霍乱疫苗的保护效力。每个人都以随机、双盲的方式接受三剂BS-WC、WC或安慰剂。在第三剂接种后长达六个月的时间里，对寻求医疗护理的病例进行监测，结果显示安慰剂组有26例确诊霍乱病例，BS-WC组有4例（保护效力85%；p<0.0001），WC组有11例（保护效力58%；p<0.01）。对于每种疫苗，在不同年龄组（2至10岁与大于10岁）以及不同严重程度的霍乱中，保护效力都是一致的。
